 Dear Reader, It's official. Elon Musk's SpaceX has confidentially filed for IPO with the U.S. SEC. The filing positions the company for a June 2026 listing … With a staggering valuation exceeding $1.75 trillion. Biggest IPO in history. But before you go out and load up on as many SpaceX shares as you can … Know this: Our expert says there's a much better way to tap into this massive IPO windfall … And most people have no idea it exists. Click here to find out more. Eliza Lasky
Weiss Ratings
Featured Article from MarketBeat Media
Eli Lilly Wins Back CVS Health, Reverting Novo's AdvantageBy Leo Miller. Date Posted: 6/2/2026. 
Key Points
- After CVS made Novo Nordisk its preferred GLP-1 provider in 2025, Lilly shares took a huge hit.
- However, CVS will restore access to both Eli Lilly and Novo's drugs, putting the firms on a level playing field.
- Lilly is now approaching its all-time high again, making its valuation something to monitor.
- Special Report: They're calling it the biggest IPO in history. I'd rather own this.
After its blockbuster Q1 2026 earnings report, which sent shares up 9.8%, pharmaceutical giant Eli Lilly and Company (NYSE: LLY) continues to rack up wins. These include a Food and Drug Administration (FDA) proposal that would pressure compounders, as well as strong clinical results for its oral GLP-1, Foundayo. Now, the company is back in the news with a key development that underscores its strong position in the GLP-1 arena. Lilly has reached an agreement with CVS Health (NYSE: CVS), the owner of the nation’s largest pharmacy benefit manager (PBM), Caremark. The agreement will extend coverage of Lilly’s top GLP-1s, allowing patients to access them through their existing insurance.
Clearly, this is a positive development, as it should increase demand for Lilly’s products. However, it also weakens Lilly’s biggest competitor, as CVS backtracks on its prior move to cut Lilly out of its coverage. CVS Reunites With Lilly After Backing NovoWith this announcement, all three of the United States' largest PBMs will soon cover Lilly’s entire portfolio of approved obesity medications. Express Scripts, owned by Cigna Group (NYSE: CI), and Optum Rx, owned by UnitedHealth Group (NYSE: UNH), already cover the drugs. Caremark will begin covering Foundayo on June 1, while coverage for Zepbound will begin on Oct. 1. What makes this announcement particularly interesting, however, is the context. Just over a year ago, CVS struck a deal with Lilly’s main competitor, Novo Nordisk A/S (NYSE: NVO). That made Novo’s Wegovy CVS’s preferred GLP-1 treatment and excluded Zepbound from coverage. Combined with its slightly disappointing earnings report on May 1, 2025, this move by Lilly’s top rival and the largest PBM sent LLY shares down almost 12%. Now, CVS has reversed that decision, which previously delivered a real blow to Lilly shares. According to a CVS spokesperson, “What this change means is that, for those clients that do (choose to provide coverage), they will have equal access to both the Novo and Lilly products, and consumers will have the same co-pays for each.” In other words, if an employer covers GLP-1s for obesity, employees can access Novo and Lilly’s products equally and for the same co-pay. This should largely reverse the negative effect of CVS’s initial decision by limiting access to Lilly’s drugs and hurting demand. Additionally, it removes the advantage Novo had as the only available option for CVS clients. Timing is another positive aspect of this decision, as Lilly is looking to increase demand for Foundayo. Its oral GLP-1 has fallen behind Novo’s Wegovy pill, which received FDA approval several months earlier. By now being on equal footing with Novo within Caremark, Lilly may have an easier time catching up. Lilly shares gained 4% on the day of the announcement as investors responded to the positive implications for the company. Zooming in on Valuation Amid Lilly’s ReboundDespite the many positive developments Lilly has seen in late 2026, the stock has underperformed overall. Shares are down around 1% compared with the S&P 500’s gain of over 10%. This comes as its latest earnings report helped kick off the recovery—before the report, shares were down nearly 21% in 2026. Now, Lilly trades less than 5% below its all-time high. Given this, it is worth examining the stock’s valuation to get a more complete understanding of the outlook for LLY shares. Currently, the stock trades at a forward price-to-earnings (P/E) ratio near 29x. This is substantially above the S&P 500’s forward P/E near 21x, and even further above the S&P 500 healthcare sector’s forward P/E near 17x. Based on these measures, Lilly’s valuation looks fairly elevated. However, when compared with Lilly’s own history, that is not the case. Over the past three years, Lilly’s average forward P/E has been nearly 43x. Thus, its current level is around 33% below that average—a much more favorable comparison. Over the past 52 weeks, Lilly’s average forward P/E has been around 30x, just slightly above its current level. Lilly’s forward P/E has also come down meaningfully from 32x, when the stock traded near its current price in February. This suggests that earnings estimates have caught up with the stock price a bit, which is a positive sign. Overall, Lilly is certainly not a cheap stock, and it will need to continue delivering strong growth to maintain its valuation. However, these metrics show that it is also not a name that necessarily screams "overvalued." Analysts Remain Constructive on Lilly’s Upside PotentialThe outlook for Lilly shares, according to Wall Street analyst price targets, remains positive. The MarketBeat consensus price target on the stock currently sits near $1,227, implying about 15% upside in shares. The average of targets updated after the company’s earnings report is moderately higher at $1,239. Among these updates, Rothschild & Co Redburn’s $900 target is the most bearish. Meanwhile, Barclays’ $1,400 target is the most bullish.
. |
Tidak ada komentar:
Posting Komentar